MedTrace Logo

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

NCT02284971 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-05-17

No results posted yet for this study

Summary

This study evaluates the combination of stereotactic body radiation therapy (SBRT) and CDX-1127 in subjects with castration resistant prostate cancer. Subjects will be randomized to one of three arms to receive SBRT prior to, after, or in conjunction with the first dose of CDX-1127.

Conditions

Interventions

BIOLOGICAL

CDX1127

RADIATION

SBRT

Sponsors & Collaborators

  • Celldex Therapeutics

    collaborator INDUSTRY

  • James Larner, MD

    lead OTHER

Principal Investigators

  • James Larner, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-04-07
Completion
2016-04-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02284971 on ClinicalTrials.gov